Belite Bio, Inc (BLTE)

NASDAQ: BLTE · Real-Time Price · USD

89.00

-3.00 (-3.26%)

At close: Oct 22, 2025, 4:00 PM EDT

89.36

+0.36 (0.40%)

After-hours: Oct 22, 2025, 4:10 PM EDT

Belite Bio Employees

Belite Bio had 25 employees as of December 31, 2024. The number of employees increased by 5 or 25.00% compared to the previous year.

Employees

25

Change (1Y)

5

Growth (1Y)

25.00%

Revenue / Employee

n/a

Profits / Employee

-$916,480

Market Cap

2.92B

Employees Chart

Employees History

Date	Employees	Change	Growth
Dec 31, 2024	25	5	25.00%
Dec 31, 2023	20	4	25.00%
Dec 31, 2022	16	4	33.33%
Dec 31, 2021	12	-	-

Related Stocks

Company Name	Employees
UnitedHealth Group	400,000
Johnson & Johnson	138,100
Thermo Fisher Scientific	125,000
Abbott Laboratories	114,000
AstraZeneca	92,900
Novo Nordisk	77,349
Novartis AG	75,883
Merck & Co.	75,000

Employee Rankings

BLTE News

7 days ago - Belite Bio Announces China NMPA Agrees to New Drug Application with Priority Review based on Interim Analysis Results for the Treatment of Stargardt Disease with Tinlarebant - GlobeNewsWire
5 weeks ago - Belite Bio Announces Completion of DRAGON, a 2-Year, Phase 3 Trial of Oral Tinlarebant in the Treatment of Stargardt Disease - GlobeNewsWire
6 weeks ago - Belite Bio Announces Up to $275 Million Upsized Private Placement Financing by Leading Healthcare Investors - GlobeNewsWire
2 months ago - Belite Bio, Inc (BLTE) Q2 2025 Earnings Call Transcript - Seeking Alpha
2 months ago - Belite Bio Reports Second Quarter 2025 Financial Results and Provides a Corporate Update - GlobeNewsWire
2 months ago - Belite Bio Announces Registered Direct Offering of $15 Million - GlobeNewsWire
4 months ago - Belite Bio Announces Completion of Enrollment in the Pivotal Global Phase 3 PHOENIX Trial Evaluating Oral Tinlarebant in Geographic Atrophy - GlobeNewsWire
5 months ago - Belite Bio Announces FDA Granting of Breakthrough Therapy Designation for Tinlarebant for the Treatment of Stargardt Disease - GlobeNewsWire